{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049544","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.320137+00:00","generated_at":"2026-06-10T09:09:15.726291+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"SCYNEXIS recalls BREXAFEMME and pauses Phase 3 MARIO study on cross-contamination risk","bullets":["GSK review found a beta-lactam drug manufactured on equipment shared with ibrexafungerp; potential cross-contamination risk.","No known contamination of ibrexafungerp and no adverse events reported; recall is out of caution.","Market recall of BREXAFEMME (ibrexafungerp tablets) and temporary hold on all clinical studies, including Phase 3 MARIO.","Mitigation strategy and resupply plan to be determined; ongoing collaboration with GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049544","json":"https://secwatch.observer/filing/0000950170-23-049544.json","markdown":"https://secwatch.observer/filing/0000950170-23-049544.md","text":"https://secwatch.observer/filing/0000950170-23-049544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023049544/0000950170-23-049544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023049544/scyx-20230919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:09:15.726291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}